Ocular Mysathenia Gravis Generalization

CompletedOBSERVATIONAL
Enrollment

151

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

January 31, 2019

Study Completion Date

January 31, 2020

Conditions
Ocular Myasthenia Gravis
Interventions
OTHER

Use of nomogram for predictions of Ocular Mysathenia Gravis generalization

The outcome measure was time to Myasthenia gravis generalization. The explanatory variables were age at onset, sex, first-year anti-acetylcholinereceptor antibody positivity, repetiting nerve stimulation showing electromyogram decrement and steroid use. Kaplan-Meier survival estimations, descriptive and multivariate Cox model analyses were computed. A nomogram combining explanatory vraiables was used to establish a score to predict the probability of OMG generalization.

Trial Locations (1)

Unknown

Antoine GUEGUEN, Paris

All Listed Sponsors
lead

Fondation Ophtalmologique Adolphe de Rothschild

NETWORK

NCT04667650 - Ocular Mysathenia Gravis Generalization | Biotech Hunter | Biotech Hunter